FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285010247> ?p ?o ?g. }

• W4285010247 endingPage "70" @default.
• W4285010247 startingPage "58" @default.
• W4285010247 abstract "Azelnidipine is a dihydropyridine used as a calcium channel blocker. The main aim of this study was to develop a validated bio-analytical method (as per US-FDA and EMA guidelines) for in vivo pharmacokinetic and bioequivalence study of azelnidipine in human plasma by LC-MS/MS, API-4000. In this method, the drug was ionized in negative mode and gave adequate response because this drug was highly sensitive and had high electron affinity due to the presence of the electron-withdrawing the nitro group in the structure of azelnidipine. The deprotonated precursor ions [M-H]- at mz-1 581.2 and consistent fragment ion selected was mz-1 491.0. For internal standard, the deprotonated precursor ions [M-H]- at mz-1 269.0 (highest peak) was observed in Q1 MS and characteristic product ions or fragment ions found in Q3 MS were at mz-1 169.8. For plasma extraction, the liquid-liquid extraction technique was used. The calibration concentrated points of azelnidipine were 0.15 to 10.00 ng mL-1 including LLOQ 0.15 ng mL-1, LQC 0.46 ng mL-1, MQC 3.75 ng mL-1 and HQC 7.50 ng mL-1. The LOD value was 0.07 ng mL-1. The result of matrix effect of internal standard (tolbutamide) ranges between 93.51% - 98.68% and 91.94% - 95.07% for azelnidipine, recovery result after extraction of plasma of azelnidipine was 90.73% to 100.46% and for IS it was 95.95% to 98.82%. After administration of film-coated azelnidipine 8mg of test drug at 2.92±0.77h. Cmax obtained was 5.98±1.93ng mL-1 whereas for reference drug it was 6.18±1.96ng mL-1 Cmax at 3.03±0.98h. This method was validated as per regulatory guidelines and is highly selective, specific, highly sensitive and reproducible with low ionic suppression and high recovery, High throughput screening method was successfully applied to in vivo pharmacokinetic and bioequivalence study of azelnidipine." @default.
• W4285010247 created "2022-07-12" @default.
• W4285010247 creator A5013956450 @default.
• W4285010247 creator A5015609305 @default.
• W4285010247 creator A5028972494 @default.
• W4285010247 creator A5029020046 @default.
• W4285010247 creator A5029384299 @default.
• W4285010247 creator A5036638461 @default.
• W4285010247 creator A5049034555 @default.
• W4285010247 date "2022-07-01" @default.
• W4285010247 modified "2023-10-18" @default.
• W4285010247 title "A NOVEL VALIDATED BIO-ANALYTICAL METHOD DEVELOPMENT FOR AZELNIDIPINE (DIHYDROPYRIDINE) IN INDIAN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY QUADRUPLE TANDEM MASS SPECTROMETRY (LC-ESI-MS/MS, API-4000) WITH AN APPLICATION TO IN VIVO PHARMACOKINETIC AND BIOEQUIVA" @default.
• W4285010247 doi "https://doi.org/10.53879/id.59.05.12787" @default.
• W4285010247 hasPublicationYear "2022" @default.
• W4285010247 type Work @default.
• W4285010247 citedByCount "0" @default.
• W4285010247 crossrefType "journal-article" @default.
• W4285010247 hasAuthorship W4285010247A5013956450 @default.
• W4285010247 hasAuthorship W4285010247A5015609305 @default.
• W4285010247 hasAuthorship W4285010247A5028972494 @default.
• W4285010247 hasAuthorship W4285010247A5029020046 @default.
• W4285010247 hasAuthorship W4285010247A5029384299 @default.
• W4285010247 hasAuthorship W4285010247A5036638461 @default.
• W4285010247 hasAuthorship W4285010247A5049034555 @default.
• W4285010247 hasConcept C113196181 @default.
• W4285010247 hasConcept C162356407 @default.
• W4285010247 hasConcept C185592680 @default.
• W4285010247 hasConcept C31827203 @default.
• W4285010247 hasConcept C43617362 @default.
• W4285010247 hasConcept C4725764 @default.
• W4285010247 hasConcept C64489805 @default.
• W4285010247 hasConcept C71043704 @default.
• W4285010247 hasConceptScore W4285010247C113196181 @default.
• W4285010247 hasConceptScore W4285010247C162356407 @default.
• W4285010247 hasConceptScore W4285010247C185592680 @default.
• W4285010247 hasConceptScore W4285010247C31827203 @default.
• W4285010247 hasConceptScore W4285010247C43617362 @default.
• W4285010247 hasConceptScore W4285010247C4725764 @default.
• W4285010247 hasConceptScore W4285010247C64489805 @default.
• W4285010247 hasConceptScore W4285010247C71043704 @default.
• W4285010247 hasIssue "05" @default.
• W4285010247 hasLocation W42850102471 @default.
• W4285010247 hasOpenAccess W4285010247 @default.
• W4285010247 hasPrimaryLocation W42850102471 @default.
• W4285010247 hasRelatedWork W1969559554 @default.
• W4285010247 hasRelatedWork W1973261120 @default.
• W4285010247 hasRelatedWork W1997103078 @default.
• W4285010247 hasRelatedWork W2008934997 @default.
• W4285010247 hasRelatedWork W2018070089 @default.
• W4285010247 hasRelatedWork W2030021314 @default.
• W4285010247 hasRelatedWork W2034852243 @default.
• W4285010247 hasRelatedWork W2046598237 @default.
• W4285010247 hasRelatedWork W2145291178 @default.
• W4285010247 hasRelatedWork W2359574775 @default.
• W4285010247 hasVolume "59" @default.
• W4285010247 isParatext "false" @default.
• W4285010247 isRetracted "false" @default.
• W4285010247 workType "article" @default.